Friday, 16 October 2026European Markets

IMERYS Stock Bullish Momentum With A 10.85% Rise On Wednesday

Loading stream...

(vianews) - the market ended the session with imerys (nk.pa) jumping 10.85% to €30.44 on wednesday while cac 40 jumped 0.91% to €7,455.64.

imerys's last close was €27.46, 36.46% below its 52-week high of €43.22.

about imerys

imerys s.a. provides mineral-based specialty solutions for various industries worldwide. the company operates through performance minerals and high temperature materials and solutions segments. it provides additives for interior decorative paints, as well as marine protection, facade coating, can coating; and adhesives and sealants. in addition, the company offers minerals for technical ceramics and traditional ceramics comprising floor and wall tiles, large slabs, sanitaryware, and tableware; and components for the production of high purity silicon metal for used to manufacture aluminum alloys, electronics, and solar panels, as well as for construction industry, such as insulation ceiling tiles. further, it provides functional additives for plastics and thermoset for use in construction and infrastructure industries; fillers and coatings for board and packaging applications; filtration agents for liquids and blood plasma; and graphite and carbon-based solutions for lithium-ion and alkaline batteries, polymers, fuel cells, carbon brushes, and others. additionally, the company offers refractory minerals and solutions for high-temperature processes; alumina and zirconia for abrasives; and high-performance binders for dry mix mortars and floor screeds in the construction industry. it serves automotive and transportation, consumer and health care, energy and electronics, industry and equipment, iron, and steel industries. the company was incorporated in 1880 and is headquartered in paris, france. imerys s.a. is a subsidiary of belgian securities bv.

earnings per share

as for profitability, imerys has a trailing twelve months eps of €1.67.

pe ratio

imerys has a trailing twelve months price to earnings ratio of 18.23. meaning, the purchaser of the share is investing €18.23 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.79%.

yearly top and bottom value

imerys's stock is valued at €30.44 at 21:35 est, way under its 52-week high of €43.22 and way higher than its 52-week low of €23.78.

sales growth

imerys's sales growth for the current quarter is negative 14.5%.

volume

today's last reported volume for imerys is 269282 which is 246.28% above its average volume of 77763.

moving average

imerys's value is higher than its 50-day moving average of €28.15 and way under its 200-day moving average of €34.27.

more news about imerys (nk.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com